MTAP is a promising target for cancer therapy.
EpidStrategies’ scientists Mina Suh, Naimisha Movva, and Sue Pastula have authored a new systematic literature review in Cancer Treatment and Research Communications. This… read more
Latest News
BlueRidge Life Sciences’ Dr. Naomi Sacks is at ISPOR!
Dr. Naomi Sacks, Vice President, BlueRidge Life Sciences’ Pharmaceutical Commercialization division, is attending the annual meeting of ISPOR (The Professional Society for Health Economics… read more
EpidStrategies Scientists in Collaboration with Duke University and the Central Brain Tumor Registry of the United States are Presenting at the 2025 SNO Pediatric Neuro-Oncology Conference
In the United States, the most common childhood central nervous system cancer is pediatric low-grade glioma, but there are no standardized coding definitions… read more
BlueRidge Life Sciences is at ISPOR 2025 in Montreal!
BlueRidge Life Sciences is at the annual meeting of ISPOR (The Professional Society for Health Economics and Outcomes Research), held this year in… read more
BlueRidge scientist Dr. Naomi Sacks co-authors study ranked in top 10% of most-viewed Obesity Science & Practice articles
BlueRidge Life Sciences Pharmaceutical Commercialization’s Dr. Naomi Sacks’s work published in Obesity Science & Practice on behalf of The Obesity Society was recently… read more
ToxStrategies and EpidStrategies are Pleased to Announce 2025 Staff Promotions
ToxStrategies and EpidStrategies are pleased to announce the promotion of 12 of our scientists, epidemiologists and engineers. We are proud to have them… read more
HEORStrategies’ Dr. Naomi Sacks is a Co-Author on a Study of Schizophrenia Treatment Patterns and Outcomes in an Integrated Delivery System
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author on a recently published study, “Impact of Demographics and Insurance Coverage on Schizophrenia Treatment… read more
ToxStrategies Acquires Suttons Creek
Partnership between leading pharmaceutical solution providers enhances offerings across pharmaceutical development and commercialization August 13, 2024 –Katy, Texas — ToxStrategies, a leading… read more